DLBCL Experts Discuss the Evolving Role of MRD in Care Decision-Making

Suzanne Fanning, DO, from Prisma Health Cancer Institute, Joshua Brody, MD, of the Tisch Cancer Institute at Mount Sinai, Ruemu Birhiray, MD, of Hematology Oncology of Indiana, and Tara Graff, DO, MS, of Mission Cancer and Blood continue their discussion on diffuse large B-cell lymphoma (DLBCL). In this segment, they survey the current utility, persisting limitations, and future potential of measurable residual disease (MRD) for management decision-making in this disease.